Header Logo

Connection

Shabir Madhi to Respiratory Syncytial Virus Infections

Back to Details
This is a "connection" page, showing publications Shabir Madhi has written about Respiratory Syncytial Virus Infections.
Shabir Madhi
Connection Strength
12,851
Respiratory Syncytial Virus Infections
  1. A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
    View in: PubMed
    Score: 0,784
  2. Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine. Obstet Gynecol. 2025 Feb 01; 145(2):147-156.
    View in: PubMed
    Score: 0,773
  3. Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date. Paediatr Drugs. 2024 Mar; 26(2):101-112.
    View in: PubMed
    Score: 0,717
  4. All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study. Lancet Infect Dis. 2023 09; 23(9):1031-1041.
    View in: PubMed
    Score: 0,689
  5. Pulmonary sequelae in 2-year-old children after hospitalisation for respiratory syncytial virus lower respiratory tract infection during infancy: an observational study. BMJ Open Respir Res. 2023 05; 10(1).
    View in: PubMed
    Score: 0,689
  6. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus. BioDrugs. 2023 May; 37(3):295-309.
    View in: PubMed
    Score: 0,688
  7. Single-dose nirsevimab prevents RSV infection. J Pediatr. 2021 01; 228:310-313.
    View in: PubMed
    Score: 0,586
  8. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020 07 30; 383(5):426-439.
    View in: PubMed
    Score: 0,569
  9. Pulmonary function sequelae after respiratory syncytial virus lower respiratory tract infection in children: A systematic review. Pediatr Pulmonol. 2020 07; 55(7):1567-1583.
    View in: PubMed
    Score: 0,560
  10. Burden of Respiratory Syncytial Virus Infection in South African Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Pregnant and Postpartum Women: A Longitudinal Cohort Study. Clin Infect Dis. 2018 05 17; 66(11):1658-1665.
    View in: PubMed
    Score: 0,488
  11. The bronchiolitis season is upon us--recommendations for the management and prevention of acute viral bronchiolitis. S Afr Med J. 2015 Sep 21; 105(7):525-6.
    View in: PubMed
    Score: 0,406
  12. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. J Clin Virol. 2006 Jul; 36(3):215-21.
    View in: PubMed
    Score: 0,212
  13. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 01; 145(2):157-167.
    View in: PubMed
    Score: 0,193
  14. Risk factors for severe respiratory syncytial virus-associated respiratory tract infection in a high HIV prevalence setting, South Africa, 2012 - 2018. BMC Infect Dis. 2024 Oct 09; 24(1):1128.
    View in: PubMed
    Score: 0,190
  15. The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children S Afr Med J. 2024 10 08; 114(10):e2582.
    View in: PubMed
    Score: 0,190
  16. Impact of Respiratory Syncytial Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection on Clinical Severity and Outcomes Among Children Hospitalized With Lower Respiratory Tract Infections in Soweto, South Africa. Pediatr Infect Dis J. 2025 Feb 01; 44(2):107-111.
    View in: PubMed
    Score: 0,190
  17. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024 Oct 24; 42(24):126276.
    View in: PubMed
    Score: 0,189
  18. Importance of nosocomial respiratory syncytial virus infections in an African setting. Trop Med Int Health. 2004 Apr; 9(4):491-8.
    View in: PubMed
    Score: 0,183
  19. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season. J Pediatric Infect Dis Soc. 2024 Feb 26; 13(2):144-147.
    View in: PubMed
    Score: 0,182
  20. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023 08 11; 228(3):299-310.
    View in: PubMed
    Score: 0,176
  21. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023 07 19; 14(1):4347.
    View in: PubMed
    Score: 0,175
  22. Respiratory syncytial virus associated illness in high-risk children and national characterisation of the circulating virus genotype in South Africa. J Clin Virol. 2003 Jul; 27(2):180-9.
    View in: PubMed
    Score: 0,174
  23. Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):273-281.
    View in: PubMed
    Score: 0,173
  24. The attributable fraction of respiratory syncytial virus among patients of different ages with influenza-like illness and severe acute respiratory illness in a high HIV prevalence setting, South Africa, 2012-2016. Int J Infect Dis. 2023 Sep; 134:71-77.
    View in: PubMed
    Score: 0,173
  25. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023 04 20; 388(16):1533-1534.
    View in: PubMed
    Score: 0,171
  26. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20; 388(16):1451-1464.
    View in: PubMed
    Score: 0,171
  27. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023 03; 7(3):180-189.
    View in: PubMed
    Score: 0,169
  28. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 05 28; 399(10340):2047-2064.
    View in: PubMed
    Score: 0,161
  29. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 03 03; 386(9):837-846.
    View in: PubMed
    Score: 0,159
  30. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022 03 03; 386(9):892-894.
    View in: PubMed
    Score: 0,159
  31. Global Respiratory Syncytial Virus-Related Infant Community Deaths. Clin Infect Dis. 2021 09 02; 73(Suppl_3):S229-S237.
    View in: PubMed
    Score: 0,153
  32. Deaths Attributed to Respiratory Syncytial Virus in Young Children in High-Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS). Clin Infect Dis. 2021 09 02; 73(Suppl_3):S218-S228.
    View in: PubMed
    Score: 0,153
  33. Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children. Pediatr Infect Dis J. 2001 Feb; 20(2):164-70.
    View in: PubMed
    Score: 0,147
  34. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 07 30; 383(5):415-425.
    View in: PubMed
    Score: 0,142
  35. Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017. Influenza Other Respir Viruses. 2020 07; 14(4):403-411.
    View in: PubMed
    Score: 0,138
  36. The Impact of Human Immunodeficiency Virus Exposure on Respiratory Syncytial Virus-associated Severe Respiratory Illness in South African Infants, 2011-2016. Clin Infect Dis. 2019 11 27; 69(12):2208-2211.
    View in: PubMed
    Score: 0,136
  37. Performance of Surveillance Case Definitions in Detecting Respiratory Syncytial Virus Infection Among Young Children Hospitalized With Severe Respiratory Illness-South Africa, 2009-2014. J Pediatric Infect Dis Soc. 2019 Sep 25; 8(4):325-333.
    View in: PubMed
    Score: 0,134
  38. The Role of Human Immunodeficiency Virus in Influenza- and Respiratory Syncytial Virus-associated Hospitalizations in South African Children, 2011-2016. Clin Infect Dis. 2019 02 15; 68(5):773-780.
    View in: PubMed
    Score: 0,129
  39. In- and Out-of-hospital Mortality Associated with Seasonal and Pandemic Influenza and Respiratory Syncytial Virus in South Africa, 2009-2013. Clin Infect Dis. 2018 01 06; 66(1):95-103.
    View in: PubMed
    Score: 0,119
  40. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017 10; 5(10):e984-e991.
    View in: PubMed
    Score: 0,117
  41. Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting. J Infect. 2017 10; 75(4):346-355.
    View in: PubMed
    Score: 0,115
  42. Challenges in estimating RSV-associated mortality rates. Lancet Respir Med. 2016 05; 4(5):345-7.
    View in: PubMed
    Score: 0,106
  43. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. J Glob Health. 2015 Dec; 5(2):020416.
    View in: PubMed
    Score: 0,103
  44. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015 Nov; 3(11):888-900.
    View in: PubMed
    Score: 0,102
  45. Deaths associated with respiratory syncytial and influenza viruses among persons =5 years of age in HIV-prevalent area, South Africa, 1998-2009(1). Emerg Infect Dis. 2015 Apr; 21(4):600-8.
    View in: PubMed
    Score: 0,098
  46. Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children <5 years of age in a high HIV prevalence setting--South Africa, 1998-2009. Clin Infect Dis. 2014 May; 58(9):1241-9.
    View in: PubMed
    Score: 0,091
  47. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. J Infect Dis. 2013 Dec 15; 208 Suppl 3:S217-26.
    View in: PubMed
    Score: 0,090
  48. Replacement and positive evolution of subtype A and B respiratory syncytial virus G-protein genotypes from 1997-2012 in South Africa. J Infect Dis. 2013 Dec 15; 208 Suppl 3:S227-37.
    View in: PubMed
    Score: 0,090
  49. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 01; 375(9725):1545-55.
    View in: PubMed
    Score: 0,070
  50. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis. 2006 Feb 15; 193(4):573-81.
    View in: PubMed
    Score: 0,052
  51. Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: the Pneumonia Etiology Research for Child Health (PERCH) study experience. Clin Microbiol Infect. 2025 Mar; 31(3):441-450.
    View in: PubMed
    Score: 0,048
  52. Mannan-binding lectin and RSV lower respiratory tract infection leading to hospitalization in children: a case-control study from Soweto, South Africa. Scand J Immunol. 2004 Jul-Aug; 60(1-2):184-8.
    View in: PubMed
    Score: 0,047
  53. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr. 2000 Jul; 137(1):78-84.
    View in: PubMed
    Score: 0,035
  54. Is Higher Viral Load in the Upper Respiratory Tract Associated With Severe Pneumonia? Findings From the PERCH Study. Clin Infect Dis. 2017 Jun 15; 64(suppl_3):S337-S346.
    View in: PubMed
    Score: 0,029
  55. Association of C-Reactive Protein With Bacterial and Respiratory Syncytial Virus-Associated Pneumonia Among Children Aged <5 Years in the PERCH Study. Clin Infect Dis. 2017 Jun 15; 64(suppl_3):S378-S386.
    View in: PubMed
    Score: 0,029
  56. Acute viral bronchiolitis in South Africa: Strategies for management and prevention. S Afr Med J. 2016 Apr; 106(4):27-9.
    View in: PubMed
    Score: 0,026
  57. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis. 2004 Dec 15; 190(12):2096-103.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.